Rheumatoid Arthritis
Conditions
Brief summary
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.
Interventions
DEVICENerve Conduction Study
Sensory and Motor Nerve Conduction study on upper and lower limbs.
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA 2. Age above 18 years old. 3. Patient cooperative and can answer questions
Exclusion criteria
1. Other rheumatologic or collagen diseases. 2. Age below 18 years and above 65 years. 3. Uncooperative patients. 4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib | 6 months | Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib in comparison to those on conventional synthetic DMARDs. |
Contacts
Primary ContactSara K Mohamed, Resident
Backup ContactAhmed R Alagamy, Associate Professor
Outcome results
None listed